1. T2D Updates From ADA 2016: New Data on Injectable Therapy and Impact on Practice

2. Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial

7. Semaglutide*

8. New Efficacy and Safety Data for Ultra-Rapid-Acting Aspart

9. Unmet Need: Ultra-Rapid-Acting Insulins

10. Faster-Acting Insulin Aspart* Onset of Action

12. Future Role of Rapid-Acting Insulin

13. New Efficacy and Safety Data for Ultra-Rapid-Acting Aspart

14. Unmet Need: Ultra-Rapid-Acting Insulins

15. Faster-Acting Insulin Aspart* Onset of Action

17. Future Role of Rapid-Acting Insulin

18. Lower Nocturnal Hypoglycemia Risk With Insulin Glargine U300 in Type 2 Diabetes

19. Concentrated Insulin Glargine U300

20. U300 Glargine Post Hoc Patient-Level Meta-Analysis

21. Clinical Use of Glargine U300

22. Reduced Hypoglycemia With Insulin Degludec in Patients With Type 1 or Type 2 Diabetes

23. SWITCH 1

24. SWITCH 2

25. Clinical Use of Degludec

26. Closing Remarks